Susan Ha
Susan Ha has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Michael J. Garabedian
Department of Microbiology, New York University Grossman School of Medicine, New York, USA
10 shared publications - Rachel Ruoff
Department of Microbiology, NYU Grossman School of Medicine, New York, New York
10 shared publications - Susan K. Logan
Department of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY, United States of America
10 shared publications - Amanda C. Kasper
Chemistry Department, New York University, New York, New York
9 shared publications - Amina Zoubeidi
Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
9 shared publications - Dafna Bar-Sagi
Department of Biochemistry and Molecular Pharmacology, New York University Grossman School of Medicine, New York, New York
9 shared publications
Latest Publications
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Chemical structures and IC50 of the multivalent ethisterone-peptoid conjugate
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Chemical structures and IC50 of the multivalent ethisterone-peptoid conjugate
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Model for MPC309 effect on AR-dependent gene expression
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Model for MPC309 effect on AR-dependent gene expression
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Effects of MPC309 versus ethisterone on gene expression in LNCaP-abl cells
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Effects of MPC309 versus ethisterone on gene expression in LNCaP-abl cells
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
PK of MPC309 and effects of MPC309 on immune cells
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
PK of MPC309 and effects of MPC309 on immune cells
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure Legends from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Figure legends for the supplemental data
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure Legends from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Figure legends for the supplemental data
- Open Access
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Comparison of MPC309 antiproliferative activity in DU145, PC3, LNCaP and 22Rv1 and effects on AR-dependent gene expression
- 19 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Comparison of MPC309 antiproliferative activity in DU145, PC3, LNCaP and 22Rv1 and effects on AR-dependent gene expression
- Open Access
- 2 October 2023
- Published by American Association for Cancer Research (AACR)
Data from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.
- 2 October 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.
- Open Access
- 2 October 2023
- Published by American Association for Cancer Research (AACR)
Data from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.
- 2 October 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.
- 24 July 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (10) , 1166-1181
A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.
- 24 July 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 22 (10) , 1166-1181
A Multivalent Peptoid Conjugate Modulates Androgen Receptor Transcriptional Activity to Inhibit Therapy-resistant Prostate Cancer
Prostate cancers adapt to androgen receptor (AR) pathway inhibitors and progress to castration resistance due to ongoing AR expression and function. To counter this, we developed a new approach to modulate the AR and inhibit castration-resistant prostate cancer (CRPC) using multivalent peptoid conjugates (MPC) that contain multiple copies of the AR-targeting ligand ethisterone attached to a peptidomimetic scaffold. Here, we investigated the antitumor effects of compound MPC309, a trivalent display of ethisterone conjugated to a peptoid oligomer backbone that binds to the AR with nanomolar affinity. MPC309 exhibited potent antiproliferative effects on various enzalutamide-resistant prostate cancer models, including those with AR splice variants, ligand-binding mutations, and noncanonical AR gene expression programs, as well as mouse prostate organoids harboring defined genetic alterations that mimic lethal human prostate cancer subtypes. MPC309 is taken up by cells through macropinocytosis, an endocytic process more prevalent in cancer cells than in normal ones, thus providing an opportunity to target tumors selectively. MPC309 triggers a distinct AR transcriptome compared with DHT and enzalutamide, a clinically used antiandrogen. Specifically, MPC309 enhances the expression of differentiation genes while reducing the expression of genes needed for cell division and metabolism. Mechanistically, MPC309 increases AR chromatin occupancy and alters AR interactions with coregulatory proteins in a pattern distinct from DHT. In xenograft studies, MPC309 produced significantly greater tumor suppression than enzalutamide. Altogether, MPC309 represents a promising new AR modulator that can combat resistant disease by promoting an AR antiproliferative gene expression program.
- Open Access
Expression of androgen receptor and its phosphorylated forms in breast cancer progression
BACKGROUND: Androgen receptor (AR) expression in breast cancers may serve as a prognostic and predictive marker. We examined the expression pattern of AR and its phosphorylated forms, Ser‐213 (AR‐Ser[P]‐213) and Ser‐650 (AR‐Ser[P]‐650), in breast cancer and evaluated their association with clinicopathological parameters.METHODS: Immunohistochemistry was performed on primary and distant metastatic breast cancers and benign breast tissue using antibodies against AR, AR‐Ser(P)‐213, and AR‐Ser(P)‐650. The levels of cytoplasmic and nuclear expression were scored semiquantitatively using a histoscore.RESULTS: Nuclear staining of AR was observed in all benign breast tissue and 67% of cancer cases. Nuclear and cytoplasmic AR‐Ser(P)‐213 was increased in breast cancers 2‐fold (P = .0014) and 1.7‐fold (P = .05), respectively, compared with benign controls, whereas nuclear and cytoplasmic AR‐Ser(P)‐650 expression was decreased in tumors by 1.9‐fold and 1.7‐fold (both P < .0001), respectively. Increased expression of nuclear or cytoplasmic AR‐Ser(P)‐213 was observed in metastatic breast cancers (1.3‐fold, P = .05), ER‐negative (2.6‐fold, P = .001), and invasive ductal carcinoma (6.8‐fold, P = .04). AR‐Ser(P)‐650 expression was downregulated in lymph node‐positive breast cancers (1.4‐fold, P = .02) but was upregulated in invasive ductal carcinomas (3.2‐fold, P < .0001) and metastases (1.5‐fold, P = .003). Moreover, in ER‐negative breast cancers, nuclear AR‐Ser(P)‐650 was decreased (1.4‐fold, P = .005), and cytoplasmic AR‐Ser(P)‐650 was increased (1.4‐fold, P = .003).CONCLUSIONS: AR and its phosphorylation at serines 213 and 650 are differentially expressed in breast cancer tumorigenesis and progression. Phosphorylation of AR at serines 213 and 650 is increased in ER‐negative breast cancers, ductal carcinomas, and metastases and may have predictive value in breast cancer prognosis. Cancer 2013;119:2532–2540. © 2013 American Cancer Society.
Open AccessExpression of androgen receptor and its phosphorylated forms in breast cancer progression
BACKGROUND: Androgen receptor (AR) expression in breast cancers may serve as a prognostic and predictive marker. We examined the expression pattern of AR and its phosphorylated forms, Ser‐213 (AR‐Ser[P]‐213) and Ser‐650 (AR‐Ser[P]‐650), in breast cancer and evaluated their association with clinicopathological parameters.METHODS: Immunohistochemistry was performed on primary and distant metastatic breast cancers and benign breast tissue using antibodies against AR, AR‐Ser(P)‐213, and AR‐Ser(P)‐650. The levels of cytoplasmic and nuclear expression were scored semiquantitatively using a histoscore.RESULTS: Nuclear staining of AR was observed in all benign breast tissue and 67% of cancer cases. Nuclear and cytoplasmic AR‐Ser(P)‐213 was increased in breast cancers 2‐fold (P = .0014) and 1.7‐fold (P = .05), respectively, compared with benign controls, whereas nuclear and cytoplasmic AR‐Ser(P)‐650 expression was decreased in tumors by 1.9‐fold and 1.7‐fold (both P < .0001), respectively. Increased expression of nuclear or cytoplasmic AR‐Ser(P)‐213 was observed in metastatic breast cancers (1.3‐fold, P = .05), ER‐negative (2.6‐fold, P = .001), and invasive ductal carcinoma (6.8‐fold, P = .04). AR‐Ser(P)‐650 expression was downregulated in lymph node‐positive breast cancers (1.4‐fold, P = .02) but was upregulated in invasive ductal carcinomas (3.2‐fold, P < .0001) and metastases (1.5‐fold, P = .003). Moreover, in ER‐negative breast cancers, nuclear AR‐Ser(P)‐650 was decreased (1.4‐fold, P = .005), and cytoplasmic AR‐Ser(P)‐650 was increased (1.4‐fold, P = .003).CONCLUSIONS: AR and its phosphorylation at serines 213 and 650 are differentially expressed in breast cancer tumorigenesis and progression. Phosphorylation of AR at serines 213 and 650 is increased in ER‐negative breast cancers, ductal carcinomas, and metastases and may have predictive value in breast cancer prognosis. Cancer 2013;119:2532–2540. © 2013 American Cancer Society.